Results 221 to 230 of about 204,259 (398)

Lack of the effect of lobeglitazone, a peroxisome proliferator-activated receptor-γ agonist, on the pharmacokinetics and pharmacodynamics of warfarin

open access: yesDrug Design, Development and Therapy, 2015
Jin Ah Jung,1 Soo-Yun Lee,2 Tae-Eun Kim,3 Jung-Ryul Kim,1 Chin Kim,4 Wooseong Huh,1,5 Jae-Wook Ko1,2 1Department of Clinical Pharmacology and Therapeutics, Samsung Medical Center, 2Department of Health Sciences and Technology, Samsung Advanced Institute ...
Jung JA   +6 more
doaj  

Pathogenic variants in chromatin‐related genes: Linking immune dysregulation to neuroregression and acute neuropsychiatric disorders

open access: yesDevelopmental Medicine &Child Neurology, EarlyView.
Chromatin machinery influences how DNA is ‘wrapped’ around histones in the nucleosome of immune and brain cells. Plain language summary: https://onlinelibrary.wiley.com/doi/10.1111/dmcn.16299 Abstract We report eight children with de novo pathogenic DNA variants in chromatin‐related genes: MORC2, CHD7, KANSL1, KMT2D, ZMYND11, HIST1HIE, EP300, and KMT2B.
Russell C. Dale   +14 more
wiley   +1 more source

Bound to bleed: How altered albumin binding may dictate warfarin treatment outcome

open access: yesInternational Journal of Cardiology: Heart & Vasculature, 2019
Although non-vitamin-K anticoagulants are now the preferred option for stroke prevention in atrial fibrillation (AF), warfarin is still used in a significant number of patients.
Anke C. Fender, Dobromir Dobrev
doaj  

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics‐Guided Warfarin Dosing: 2017 Update

open access: yesClinical pharmacology and therapy, 2017
Julie A. Johnson   +15 more
semanticscholar   +1 more source

Recombinant Activated Factor VIIa Combined With Tranexamic Acid Control Haemostasis in Patients With Severe Factor XI Deficiency Undergoing Urological Procedures

open access: yesHaemophilia, EarlyView.
ABSTRACT Introduction Patients with severe Factor XI deficiency face unique challenges during urological procedures due to an elevated risk of bleeding, balanced against the use of tranexamic acid (TXA), which may form blood clots. Given the limitations associated with plasma‐based treatment, there have been reports of successful and safe off‐label use
Neta Sternbach   +7 more
wiley   +1 more source

Mechanism of exacerbation of traumatic brain injury under warfarin anticoagulation in male mice.

open access: yesPLoS ONE
IntroductionTraumatic brain injury (TBI) is exacerbated in patients on antithrombotic medications, with warfarin leading to increased bleeding in some cases.
Yuki Tatara   +3 more
doaj   +1 more source

Effectiveness and safety of antithrombin for treatment of portal vein thrombosis: Nationwide prospective surveillance of 4 years of clinical experience in Japan

open access: yesHepatology Research, EarlyView.
Abstract Aim Antithrombin (AT), a plasma protein with anticoagulant properties, has a long‐standing medical history, primarily for treatment of congenital AT deficiency. Accumulated clinical experiences suggest AT is a potential anticoagulant for thrombotic diseases. This study aimed to clarify the effectiveness, safety, and clinical significance of AT
Shoichi Matsutani   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy